LeonaBio (LONA) Common Equity (2019 - 2026)
LeonaBio (LONA) posted quarterly Common Equity of $49.3 million for Q1 2026, up 32.07% year-over-year from $37.3 million in Q1 2025, and up 77.41% quarter-over-quarter from $27.8 million in Q4 2025.
LeonaBio (LONA) Common Equity (2019 - 2026) Analysis & Trends
LeonaBio (LONA) has reported Common Equity for 8 consecutive years, with $49.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity rose 32.07% year-over-year to $49.3 million; the TTM figure through Mar 2026 stood at $49.3 million (up 32.07% YoY), while the FY2025 annual figure was $27.8 million, down 38.03% from the prior year.
- Common Equity improved to $49.3 million in Q1 2026 per LONA's latest filing, from $27.8 million in the prior quarter.
- Across five years, Common Equity topped out at $302.0 million in Q1 2022 and bottomed at $26.8 million in Q3 2025.
- Historically, Common Equity has averaged $131.0 million across 5 years, with a median of $106.7 million in 2024.
- Annual changes were most pronounced in 2024 — Common Equity sank 65.56% — and 2026, when it jumped 32.07%.
- LeonaBio's Common Equity stood at $235.1 million in 2022, then plunged by 44.63% to $130.2 million in 2023, then tumbled by 65.56% to $44.8 million in 2024, then plunged by 38.03% to $27.8 million in 2025, then jumped by 77.41% to $49.3 million in 2026.
- Business Quant data shows LONA's Common Equity at $49.3 million in Q1 2026, $27.8 million in Q4 2025, and $26.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.79 Bn |
| 10 | LeonaBio | 180.91 Mn | 129.85 Mn | - | 33.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 49.30 Mn |
| Dec 31, 2025 | 27.79 Mn |
| Sep 30, 2025 | 26.79 Mn |
| Jun 30, 2025 | 31.99 Mn |
| Mar 31, 2025 | 37.33 Mn |
| Dec 31, 2024 | 44.84 Mn |
| Sep 30, 2024 | 57.58 Mn |
| Jun 30, 2024 | 83.34 Mn |
| Mar 31, 2024 | 106.74 Mn |
| Dec 31, 2023 | 130.19 Mn |
| Sep 30, 2023 | 154.76 Mn |
| Jun 30, 2023 | 184.98 Mn |
| Mar 31, 2023 | 211.13 Mn |
| Dec 31, 2022 | 235.14 Mn |
| Sep 30, 2022 | 262.25 Mn |
| Jun 30, 2022 | 280.57 Mn |
| Mar 31, 2022 | 301.98 Mn |
| Dec 31, 2021 | 321.08 Mn |
| Sep 30, 2021 | 336.24 Mn |
| Jun 30, 2021 | 350.71 Mn |